Clinical Trials in the USA / NCT06355791
Recruiting
Not applicable
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
NCT06355791 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Degenerative Conditions of the Lumbar SpineLumbar Spinal StenosisSpondylolisthesis
Investigational drug(s) / intervention(s)
Minuteman G5 Device
Minuteman G5 Device: The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
Study summary
This is a prospective, multi-center open-label single arm post-market study where the purpose is to evaluate the effectiveness and safety of the market approved Spinal Simplicity Minuteman G5 MIS Fusion Plate and bone graft material in patients with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication. The indication for the device under study is degenerative conditions of the lumbar spine resulting in back pain with lower extremity symptoms and neurogenic claudication.
Eligibility
Inclusion Criteria
A subject must MEET ALL of the following inclusion criteria:
1. Be a candidate for Spinal Simplicity Minuteman G5 Fusion Plate device per labeled indication
2. Be willing and capable of giving written consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided
3. Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand the written informed consent
4. Be 18 years of age or older at the time of enrollment
5. Have been diagnosed with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication
6. Received at least 3 months of non-operative or conservative treatment without significant benefit in the opinion of the Investigator
7. Be willing and able to comply with study-related requirements, procedures and visits
8. Be on a stable pain medication regimen, as determined by the Investigator, for at least 30 days prior to enrolling in this study.
9. Must disclose any unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the Investigator. Including being involved in an injury claim under current litigation or has a pending or approved worker's compensation claim. Subjects will not be excluded due to secondary gain, but it should be disclosed at Enrollment.
Exclusion Criteria
A subject must NOT MEET ANY of the following exclusion criteria:
1. Had previous spinal surgery at the level of intervention (e.g. lumbar fusion, discectomy, Laminectomy) MILD procedure is not considered an exclusion.
2. Patient physically unable to perform the Gait and/or Balance tests.
3. Current systemic infection or local infection increasing the risk of surgery
4. History of medications decreasing bone quality or soft tissue healing in the opinion of the Investigator
5. Grade II-V spondylolisthesis
6. Significant scoliosis with Cobb angle \>10 degrees
7. Unremitting back pain in a spinal flexion position
8. Active systemic disease that may affect the welfare of the subject in the opinion of the Investigator
9. Be concurrently participating in another clinical drug and/or device study that may alter or confound the results of the assessment (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) as determined by the investigator.
10. Vertebral osteoporosis or history of vertebral fracture
11. Be pregnant/ lactating or plan to become pregnant from study enrollment through 3 months post-operatively. (determined by urine testing unless female subject is surgical sterile or post-menopausal). If female, sexually active and childbearing age, subject must be willing to use a reliable form of birth control through the 3-month visit.
12. Malformation or dysplasia of spinous process
13. Severe osteoporosis with T score \<-2.5 SD
Primary outcome measure(s)
- Pain (Overall, Back and Leg) using NRS/numeric rating scale — Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
Overall pain, as well as back pain when standing/walking and leg pain when standing will be assessed using a numeric rating scale (NRS). The NRS is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable. - Oswestry Disability Index (ODI) — Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
ODI is a self-reported questionnaire widely used to track changes in a patient's condition over time and evaluate the effectiveness of treatments for low back pain. The ODI consists of 10 sections, each addressing a specific aspect of daily functioning. A higher score indicates greater disability. The final score/index ranges from 0-100 scale. A score of 0-20 reflects minimal disability, 21-40 moderate disability, 41-60 severe disability, 61-80 crippled, and 81-100 bed-bound. - PROMIS 29 2.0 — Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
PROMIS-29 c2.0 is a set of standardized questions that measures 29 items across 7 domains of physical and mental health. PROMIS-29 profile assesses pain intensity using a single 0-10 numeric rating scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable. And seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. Each domain is scored on T-Score Scale ranging between 22.9- 81.6 with a mean of 50 and a standard deviation of 10. - Assessment of Motion using BioMech Lab testing equipment — Baseline and 1-, 3- and 12-months post implantation.
A Primary Objective of this study is to collect real-world functional outcomes assessment of motion following treatment with the market-released Spinal Simplicity Minuteman G5 Device using BioMech Lab equipment to record gait and balance. The BioMech Lab motion analytics system will assess gait and balance via sensors placed before physical testing. - Zurich Classification Questionnaire (ZCQ) — Baseline and 1-, 3- 6- and 12-months post implantation; annually out to five years.
The ZCQ Symptom Severity, Physical Function and Subject Satisfaction allows subjects to rate their symptoms, function or satisfaction on a scale based on their experience over the past week. Symptom Severity domain evaluates the intensity of symptoms such as pain and numbness. It comprises seven items, each rated on a scale from 1 to 5. Overall symptom score ranges from 7-49; with higher scores indicating more severe symptoms. Physical Function domain assesses the impact of symptoms on daily activities. It includes five items, scored on a 1 to 4 scale. Overall symptom score ranges from 5-20; where higher scores denote greater functional impairment. Subject Satisfaction domain measures patient satisfaction with treatment outcomes. It consists of six items, each rated from 1 to 4, with higher scores reflecting greater dissatisfaction. Overall Satisfaction ranges from 6-24: where higher scores denote greater dissatisfaction.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Vista Clinical Research | Newnan | Georgia | Recruiting |
| Comprehensive Pain & Spine Specialists | Indianapolis | Indiana | Recruiting |
| University of Kansas Medical Center | Kansas City | Kansas | Not Yet Recruiting |
| Nura Precision Pain Management | Edina | Minnesota | Recruiting |
| Pacific Sports & Spine | Eugene | Oregon | Recruiting |
| Spine & Nerve Center of the Virginias | Charleston | West Virginia | Recruiting |
More Spinal Simplicity LLC trials in the USA
Other trials for the same condition
LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis
Active, not recruiting
Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft.
Active, not recruiting
Kore Fiber PLF Study
Starting soon
Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures
Enrolling by invitation
Advanced Materials Science in XLIF Study
Enrolling by invitation
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06355791 on ClinicalTrials.gov ↗ ← All trials in the USA